StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- Most Volatile Stocks, What Investors Need to Know
- High-Yield Texas Instruments Could Hit New Highs Soon
- EV Stocks and How to Profit from Them
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Are Penny Stocks a Good Fit for Your Portfolio?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.